SEC Form 10-K filed by VolitionRX Limited
$VNRX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2025 | $2.50 | Buy | H.C. Wainwright |
| 2/1/2023 | Buy → Hold | The Benchmark Company | |
| 2/17/2022 | $8.00 → $7.00 | Overweight | Cantor Fitzgerald |
| 11/16/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
Conference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025. Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of
HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium. Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its regulatory transition program for Nu.Q® NETs (from IVDD to IVDR), the continued research and development of a Lateral Flow product, specifically to enable access to its Nu.Q® NETs product in Low Income Countries and more.Mr. Nicolas Delahaye, Corporate Relations Manager, Namur
Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock JournalHENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma. Principal Investigator and Senior Author, Myung S. Park, Professor of Surgery, Associate Medical Director of Research, Trauma Center, Director, Clinical Research Trials Unit, Center for Cl
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
10-K - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)
8-K - VOLITIONRX LTD (0000093314) (Filer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
4 - VOLITIONRX LTD (0000093314) (Issuer)
H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50
The Benchmark Company downgraded VolitionRx from Buy to Hold
Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G - VOLITIONRX LTD (0000093314) (Subject)
SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)
HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas
HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a
Conference call to discuss financial and operational results scheduled forWednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025. Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of
Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference CallDate: Wednesday, April 1, 2026Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (t
Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter of 2025 and to provide a business update. Details of this event can be found below. Event: VolitionRx Limited Third Quarter 2025 Earnings and Business Update Conference Call Date: Friday, November 14, 2025Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800